Mechanisms of Physical Activity Limitation in Chronic Lung Diseases

doi:10.1155/2012/634761

Pulm Med. 2012; 2012: 634761.

Published online 2012 December 12. doi: 10.1155/2012/634761

PMCID: PMC3530855

Mechanisms of Physical Activity Limitation in Chronic Lung Diseases

Ioannis Vogiatzis,^1
,^2
,^3
,⁴^* George Zakynthinos,³ and Vasileios Andrianopoulos⁴

¹Department of Physical Education and Sport Sciences, National and Kapodistrian University of Athens, 17237 Athens, Greece

²Institute of Clinical Exercise and Health Science, University of West of Scotland, Hamilton ML3 0JB, UK

³1st Department of Critical Care Medicine, National and Kapodistrian University of Athens, 10675 Athens, Greece

⁴Thorax Foundation, Research Centre of Intensive and Emergency Thoracic Medicine, 10675 Athens, Greece

*Ioannis Vogiatzis: Email: gianvog/at/phed.uoa.gr

Academic Editor: Denis O'Donnell

Received July 25, 2012; Accepted September 26, 2012.

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

In chronic lung diseases physical activity limitation is multifactorial involving respiratory, hemodynamic, and peripheral muscle abnormalities. The mechanisms of limitation discussed in this paper relate to (i) the imbalance between ventilatory capacity and demand, (ii) the imbalance between energy demand and supply to working respiratory and peripheral muscles, and (iii) the factors that induce peripheral muscle dysfunction. In practice, intolerable exertional symptoms (i.e., dyspnea) and/or leg discomfort are the main symptoms that limit physical performance in patients with chronic lung diseases. Furthermore, the reduced capacity for physical work and the adoption of a sedentary lifestyle, in an attempt to avoid breathlessness upon physical exertion, cause profound muscle deconditioning which in turn leads to disability and loss of functional independence. Accordingly, physical inactivity is an important component of worsening the patients' quality of life and contributes importantly to poor prognosis. Identifying the factors which prevent a patient with lung disease to easily carry out activities of daily living provides a unique as well as important perspective for the choice of the appropriate therapeutic strategy.

1. Exercise Intolerance

Exercise intolerance is a condition where the individual is unable to perform physical exercise at the intensity or for the duration that would be expected of someone in his or her age and general physical condition. When this inability is caused by impaired function of one or more of the major physiological systems, namely the respiratory, the cardiovascular, and the peripheral muscle metabolic system, the result is the amplification of the perceptions of respiratory discomfort, either alone or typically in conjunction with peripheral muscle discomfort/fatigue [1]. In patients with chronic lung diseases, dyspnea sensations are exaggerated during exercise secondary to the reduced breathing efficiency that results from the deteriorating ventilatory mechanics on one hand and the increased ventilatory requirement on the other hand (Figure 1).

Figure 1

Conceptual framework of factors limiting exercise tolerance in COPD. Mismatch of ventilatory capacity and ventilatory demand/workload. Ventilatory capacity is reduced in patients with COPD and is thus insufficient to match the ventilatory requirement (more ...)

Respiratory discomfort is typically perceived as the distressing sensation of unsatisfied inspiration because of a mismatch between central neural drive and the respiratory mechanical/muscular response (i.e., the so-called “neuromechanical uncoupling or dissociation”) of the respiratory system [2]. Patients with chronic lung diseases constantly select descriptor clusters that allude to both “increased respiratory work/effort” and “unsatisfied inspiration” upon cessation of physical exercise. Recent theories on the mechanisms of respiratory discomfort have emphasized the central importance of the perception of increased contractile inspiratory muscle effort (dyspnea perceived as “increased respiratory effort”) [3]. In fact, inspired effort and central motor command output are both increased compared to healthy individuals, reflecting the relatively higher ventilation, as well as the increased loading and functional weakness of the inspiratory muscles [4, 5]. Particularly in patients with chronic obstructive pulmonary disease (COPD) altered afferent information from activated mechanoreceptors in the overworked and shortened inspiratory muscles, secondary to dynamic lung hyperinflation, may contribute to an increased sense of work or effort, but this remains speculative [6, 7]. It has long been suggested that in these patients, a mismatch between central neural drive and the respiratory mechanical/muscular response (“neuromechanical uncoupling” or dissociation) of the respiratory system, as crudely reflected by the increased effort-displacement ratio, is fundamental to the origin of perceptions of unrewarded inspiratory effort (i.e., “unsatisfied inspiration”) [2, 8].

Peripheral muscle contractile fatigue occurring secondary to a limitation in oxygen supply to, and/or utilization of oxygen by, the mitochondria [9] also constitutes an important factor that limits exercise capacity in patients with chronic lung diseases. This suggestion is further supported by the finding that the degree of exercise-induced quadriceps muscle fatigue in COPD negatively correlates with peak oxygen utilization [10]. A decrease in locomotor muscle force output compared to the predicted normal values has also been reported in patients with interstitial lung disease (ILD) [11] and pulmonary arterial hypertension (PAH) [12].

Accordingly, it is likely that cellular oxygen demand either exceeds the normal maximal oxygen transfer capacity of the oxygen transport chain, (i.e., when maximal oxygen consumption has been truly achieved), or stresses an impaired physiological system (i.e., cardiovascular and/or respiratory) preventing the achievement of a true maximal oxygen consumption. Hence, the factors that limit physical performance in healthy individuals (i.e., when oxygen demand exceeds the normal maximal oxygen transfer capacity) are different to those (i.e., impairment in oxygen transport) constraining the capacity to perform physical exercise in patients with chronic lung diseases (i.e., ventilatory limitation) [9, 13].

2. Physiological Factors Impairing Physical Activity

Exercise intolerance in patients with chronic lung diseases is multifactorial, involving ventilatory, gas exchange, cardiovascular, and peripheral muscle abnormalities.

2.1. Ventilatory Constraints

During incremental exercise, healthy elderly individuals can sufficiently increase their breathing frequency and their tidal volume to provide up to a 10–15 fold increase in minute ventilation that is essential to clear the carbon dioxide production and meet the increased oxygen demand [14–17]. Under such circumstances, ventilatory function is often not the limiting factor, at least for a wide range of submaximal exercise levels, as minute ventilation ( equation M1

) is maintained well below the maximum ventilatory capacity (MVC) [18]. Ventilatory limitation, however, may occur in healthy elderly individuals, particularly women [19] during maximal exercise, as the ratio of equation M2

to MVC (

) approaches or even exceeds 85% [20, 21]. While an increased ratio (i.e., >85%) of peak exercise ventilation to the estimated MVC strongly suggests limiting ventilatory constraints, a preserved peak equation M4

/MVC ratio (i.e., <75% predicted) by no means excludes the possibility of significant ventilatory impairment during intense physical activity [22–26].

Patients with chronic lung diseases are deemed to have ventilatory limitation if, at cessation of exercise, the patient has reached estimated MVC, while at the same time cardiac and other physiological functions are operating below maximal capacity. Hence, attendant respiratory discomfort may limit exercise capacity before actual physiological limitation occurs, and the relative importance of other nonventilatory factors is impossible to quantify with precision. Thus, simultaneous analysis of exercise flow-volume loops at the point of exercise limitation may show marked constraints on flow and volume generation in the presence of an apparently adequate ventilatory reserve as estimated from the peak equation M5

/MVC ratios [22–26]. In a recent study, 14% of a population sample of clinically stable patients with COPD (n = 105), with apparent ventilatory reserve at peak exercise (i.e., equation M6

predicted) had coexisting limiting restrictive ventilatory constraints [i.e., behaved as if they had a restrictive ventilatory defect due to constrained ability to increase V_T when end-inspiratory lung volume (EILV) approached total lung capacity (TLC)] as indicated by an EILV >95% of TLC that is, significantly reduced peak inspiratory reserve volume (IRV) at the same time point [24]. In addition, significant ventilatory constraints may be detected on exercise flow-volume loop analysis, even in patients with mild COPD [22, 25, 26] who have an apparently normal ventilatory reserve at peak exercise, as ascertained again by the peak equation M7

/MVC method. Therefore, the role of exercise flow-volume loop analysis combined with the behavior of dynamically assessed operating lung volumes is crucial in ascertaining the presence or not of significant ventilator constraints in all chronic pulmonary diseases.

In the majority of patients with chronic lung diseases, a disparity is developed between the decreased ventilatory capacity, which is manifested by diminished maximum and sustainable voluntary capacity and eventually by the inability to sufficiently increase minute ventilation during intense physical activities, and the increased ventilatory requirement of exercise [14, 27]. This disparity leads to intense dyspnea sensation that is the symptom limiting physical activity in a large fraction of patients with chronic lung diseases [28, 29]. The factors contributing to decreased ventilatory capacity or increased ventilatory requirement/workload are in brief described below (Figure 1).

2.1.1. Reduced Ventilatory Capacity

Reduced ventilatory capacity during intense physical activity is due to the abnormal respiratory system mechanics and the dysfunction of the respiratory muscles. In patients with chronic lung diseases, the high inspiratory (and expiratory) airway resistance and/or reduced lung compliance (that occurs in ILD and in COPD when breathing on the flat portion of the pressure/volume relationship) can substantially increase the pressure requirement for airflow and thus increase the work of breathing [29–31]. Respiratory muscles are frequently weakened and unable to endure a given workload adequately due to the presence of hyperinflation and/or intrinsic muscle dysfunction/hypoperfusion.

2.1.2. Ventilatory Demand

Ventilatory demand is increased during intense physical activity owing to gas exchange abnormalities (i.e., worsening of alveolar ventilation/perfusion [ equation M8

] mismatch and increased dead space ventilation) which lead to hypoxemia and hypercapnia [20]. The ventilatory demand of exercise is regulated not only by the metabolic rate but also by the arterial carbon dioxide tension (PaCO₂) and the physiological dead space fraction of breath [32]. Metabolic acidosis also increases the ventilatory requirement of intense physical activity [33]. Therefore, in chronic lung diseases, for a given rate of CO₂ output ( equation M9

) and PaCO₂, equation M10

is usually increased because of higher dead space ventilation [1] (Figures (Figures22 and and3).3). Moreover, ventilatory workload is increased during exercise because of abnormal dynamic ventilatory mechanics.

Figure 2

Mean arterial oxygen and carbon dioxide tension during exercise in chronic lung diseases. Arterial oxygen tension (PaO₂) and carbon dioxide tension (PaCO₂) as a function of oxygen uptake at rest and during high-intensity exercise in COPD (a and b; range (more ...)

Figure 3

Mean minute ventilation and cardiac output during exercise in chronic lung diseases. Minute ventilation (V_E) and cardiac output as a function of oxygen uptake at rest and during exercise in patients with COPD (a and b), ILD (c and d), PVD (e and f), and (more ...)

In practical terms, during incremental cardiopulmonary exercise testing, exercise intolerance in patients with COPD is typically manifested by reduced peak oxygen uptake (Figure 4(a)) and an early occurrence of the lactate threshold secondary to premature lactic acidosis [14, 33–38]. Early termination of exercise is also accompanied by low peak equation M11

, substantial ventilatory inefficiency (marked by increased ventilatory equivalents for carbon dioxide), and decreased ventilatory reserve (i.e., evident by increased peak

Figure 4

Ventilatory and gas exchange responses during incremental exercise in chronic lung diseases. Typical exercise responses in COPD ( [open triangle]

) interstitial lung disease (ILD: ●), PVD (■), and healthy age-matched subjects (-

-) (more ...)

Typically, minute ventilation increases progressively with increasing exercise intensity in COPD in such a manner that the relationship between ventilation and work rate or oxygen uptake often has a sharper slope when compared to that recorded in healthy age-matched individuals. This is because at a given level of external submaximal intensity, minute ventilation is higher than in healthy subjects owing to increased dead space ventilation (Figure 3(a)). Consequently, at a given work or metabolic rate COPD patients endure a considerably greater work of breathing than their healthy counterparts owing to the higher ventilatory rate per se and also to the higher cost per liter of ventilation. The latter is due to the fact that abnormal dynamic ventilatory mechanics of COPD require a greater degree of effort to move a given volume of air.

Expansion of tidal volume is also restricted secondary to the development of dynamic hyperinflation, whereas breathing frequency is increased (Figure 4(b)). Repeated measurements of inspiratory capacity during exercise demonstrate a progressive decrease in this variable indicating that end-expiratory lung volume has been increased [39, 40].

In summary, the deteriorating ventilatory mechanics and the increased ventilatory requirement occurring even during mild to moderate physical exertion in patients with chronic lung diseases worsens breathing efficiency, thereby exaggerating dyspnea sensations.

2.2. Gas Exchange Limitations

Age-related changes in pulmonary circulation would be expected to make elderly individuals more susceptible to gas exchange abnormalities during exercise. However, despite the deterioration in ventilatory reserve with aging, healthy older adults appear able to maintain alveolar ventilation at a level that allows maintenance of arterial blood gases within normal limits, even during heavy exercise [5, 18, 20, 41]. Accordingly, equation M13

remains near unity as both ventilation and perfusion increase several-fold with increasing intensity of physical activity. Moreover, alveolar-capillary diffusion also remains intact, and consequently PaO₂ remains normal, even at a high-intensity physical activity [14, 18, 20] (Figure 2(a)). Furthermore, in healthy elderly individuals, exercise-induced tidal volume (V_T) increase occurs in the setting of relatively fixed anatomic dead space (V_D), so the V_D/V_T ratio decreases such that effective alveolar ventilation increases as a proportion of the increased minute ventilation.

In contrast, gas exchange regulation is impaired in chronic lung diseases that involve the airways, the pulmonary vasculature, and the alveolar-capillary interface to varying degrees thereby producing varying degrees of abnormal

inequalities, diffusion impairment, and hypoxemia during exercise. In fact, many patients with severe lung disease experience arterial oxygen desaturation during exercise. Furthermore, in Chronic Lung Diseases that affect the pulmonary vasculature, arterial PCO₂ may be higher than in healthy subjects as V_D is increased owing to reduced

[3, 29, 42, 43] (Figure 2(b)).

Measurement of physiological dead space (V_D physiological) requires the assumption that the PCO₂ of the exchanging (i.e., perfused) alveoli equals PaCO₂. Normally V_D physiological is approximately equal to anatomical dead space (V_D anatomical) and accounts for about 25%–30% of V_T at rest. It is increased with exercise, consequent to the expanding influence on the conducting airways of the greater transpulmonary pressures. However, as the expansion of the alveolar space is appreciably greater than that of the less distensible conducting airways, V_D physiological/V_T falls (typically to ~0.1-0.2 at peak exercise). Naturally, V_D physiological/V_T is appreciably larger than V_D anatomical in many pulmonary diseases, with V_D physiological/V_T being as high as 0.5.

Due to the early termination of exercise, peak heart rate is relatively low whilst the heart rate reserve is high. In addition, patients often exhibit arterial hypoxemia (Figure 4(c)) that is manifested by a decrease in arterial oxygen saturation. Furthermore, owing to the reduced alveolar ventilation during exercise, hypercapnia emerges reflecting overt ventilatory insufficiency. In addition, in patients with COPD mechanical factors may substantially constrain the ventilatory response to the metabolically generated CO₂ in such a way that PaCO₂ may not decrease as in normal healthy subjects (i.e., compromised respiratory compensation) [44–47] (Figure 2(b)). Indeed, severe mechanical restriction secondary to dynamic hyperinflation and increased respiratory muscle work in a setting of an increased physiological dead space has been recognised as a contributory factor to hypercapnia in COPD [48].

In summary, during prolonged exercise the aforementioned gas exchange abnormalities worsen the alveolar ventilation/perfusion inequalities further increasing dead space ventilation that in turn leads to hypoxemia and hypercapnia. All these factors contribute to increased ventilatory requirement that in the face of reduced ventilator capacity exaggerate dyspnea sensations, thereby compromising physical capacity.

2.3. Central and Peripheral Hemodynamic Factors

Cardiac output in healthy elderly subjects can increase several-fold in response to exercise [5, 18, 20, 49, 50]. In the majority of healthy elderly subjects, cardiac output is often the “rate-limiting step” to exercise, and normal maximal exercise is usually accompanied by a heart rate that often approaches the maximal predicted. In contrast, in chronic lung diseases, the following mechanisms that involve oxygen transport are frequently impaired resulting in reduction of cardiovascular function (Figure 3). Firstly, coexisting right or left ventricular dysfunction can impair physical activity simply because of poor cardiac output capability, which often leads to impaired oxygen delivery and early development of metabolic acidosis. Similarly, functionally important arrhythmias may also impair the normal increase in cardiac output as a function of an increase in work rate [5, 18, 20, 51]. Secondly, in chronic lung diseases, especially in the presence of pulmonary vascular abnormalities, pulmonary hypertension and right ventricular dysfunction may develop [52]. The impaired right ventricle may thus contribute to a limited increase in cardiac output. These phenomena may worsen in the presence of hypoxemia. Hypoxemia can in turn elevate pulmonary vascular resistance and create pulmonary arterial hypertension with consequent right heart failure [43, 52–58]. The resulting restrained increase in cardiac output, coupled with the low oxygen content, reduces systemic oxygen delivery to all organs of the body, including skeletal muscles. Interestingly, because the work of breathing is often substantially increased in chronic lung diseases, there might also exist a respiratory muscle “steal” of blood flow away from the locomotor muscles, which further compromises peripheral muscle function [59, 60].

In COPD, constant-load exercise tolerance has been documented to largely depend on the imposed workload as the time to the limit of tolerance decreases (similarly to normal subjects) hyperbolically as a function of power output [61]. The hyperbolic shape of the power output-endurance time relationship has been shown to be determined by the dynamics of the ventilatory response toward a reduced and fixed maximum ventilatory ceiling. More explicitly, for each individual COPD patient there is a so-called “critical power” that represents the highest work rate at which there is sufficient ventilatory reserve. In terms of physiological responses, studies [62, 63] have revealed that in the transition from rest to constant-load exercise, pulmonary oxygen uptake kinetic responses are slower in patients with COPD as compared to age-matched healthy individuals. This sluggishness of oxygen uptake is thought to lead to an early and greater reliance on oxygen-independent metabolic pathways and accumulation of by-products that accelerate the occurrence of muscle fatigability. Along these lines, there is uniform agreement [14, 33–38] that lactic acid production occurs at a very low level of physical activity in COPD (i.e., <40% predicted peak equation M16

) [27, 60, 64]. In addition, derangements in the diffusive and convective transport of oxygen to skeletal muscle mitochondria have been portrayed as plausible factors to delayed pulmonary oxygen uptake kinetics [62, 63, 65]. Chiappa and colleagues [66] extended those findings by showing that COPD patients also display slower cardiac output kinetics along with faster dynamics of vastus lateralis muscle deoxygenated haemoglobin (an index of muscle microvascular oxygen extraction). These findings have been interpreted to indicate impaired central and peripheral muscle hemodynamic adjustments in COPD compared to healthy subjects [66, 67].

In summary, in chronic lung diseases cardiovascular factors associated with coexisting right and/or left ventricular dysfunction, functional arrhythmias, and various negative cardiopulmonary interactions can impair cardiac function and thus physical activity.

2.4. Skeletal Muscle Abnormalities

Regardless of overt respiratory insufficient, patients with chronic lug diseases are commonly characterized by reduced physical activity. Inactivity in COPD leads to muscle weakness and altered muscle fibre distribution [68] reflected by high proportion of type I slow twich fibres which are highly oxidative, low tensioned, and fatigue resistant [12, 69–74]. Reduction in the proportion of oxidative fibres reduces the oxidative potential of the muscles and would make them more vulnerable to fatigue during high-intensity exercise. There is also less capillary density that reduces regional blood flow and oxygen/nutrient delivery. Such structural and metabolic abnormalities of the limb muscles may lead to early lactic acidosis and task failure with exercise [69–73].

In addition, systemic inflammatory mediators, which can profoundly affect skeletal muscle function [44, 75–77] are persistently elevated in chronic lung diseases, thereby accelerating muscle protein degradation [78–85]. This contributes to the loss of muscle mass and the clinical appearance of “muscle wasting” [44, 75–77, 85–87]. Chronic inflammation also increases muscle oxidative stress and increases reactive oxygen species, which directly damage muscle proteins, impair their function, and lead to protein degradation [29, 88–90].

Furthermore, patients with chronic lung diseases [27] are often malnourished. Weight loss occurs in approximately 30% of out-patients with chronic lung diseases [91–96], because of decreased calorie intake and the effects of chronic inflammation on energy metabolism in general. Reduced protein intake leads to muscle breakdown as muscle proteins and amino acids are utilized for fuel (catabolism). Malnutrition also contributes to reduced muscle enzyme capacity and reduced availability of energy substrates [97–101]. Finally, patients with chronic lung disease may also take corticosteroids, particularly during exacerbations. Corticosteroids can profoundly affect skeletal muscle, as they reduce contractile proteins, increase protein breakdown and turnover, downregulate growth factors, reduce glycolytic activity, and lead to sarcomere and type-II fibre atrophy [102–104].

Accordingly, lower limb muscles in patients with chronic lung diseases are atrophied, weak, fatigable, and metabolically inefficient. These unfavorable muscle characteristics concur to limit exercise capacity, a most debilitating feature in these patients.

In summary, although several mechanisms underlying the development of skeletal muscle dysfunction have been identified (e.g., deconditioning), it is important to further identify the impact of other potential contributors to skeletal muscle dysfunction in chronic lung diseases (such as inflammation, malnutrition, oxidative stress, and inflammation, etc).

2.5. Exercise Intolerance in Chronic Lung Diseases

In patients with COPD, exercise intolerance involves respiratory mechanical, pulmonary gas exchange, hemodynamic and peripheral muscle abnormalities that interfere with the normal in-series system (ventilation, gas exchange, blood flow, hemoglobin, muscle O₂/CO₂ transport, and O₂ utilization/CO₂ production) upon which exercise depends, thereby ultimately preventing adequate oxygen transfer from the atmosphere to, and/or utilization of oxygen by, the mitochondria. Such abnormalities may occur consequently due to the following reasons: (i) limited ventilatory capacity to suffice the ventilatory requirement, (ii) imbalance between the high blood/oxygen requirement of the locomotor and/or respiratory muscles and the limited blood/oxygen supply to these muscles, and (iii) dysfunction/weakness and reduced oxygen utilization capacity at the level of the peripheral muscles [1–13].

The primary mechanisms limiting exercise tolerance in patients with ILD include the restrictive lung mechanics, pulmonary gas exchange derangements, hemodynamic abnormalities, and peripheral muscle dysfunction [4]. Ventilatory inefficiency occurs secondary to high physiological dead space and arterial hypoxemia and thirdly to premature metabolic acidosis. Likewise, the oxygen cost of breathing per unit ventilation is increased in patients with ILD as the static recoil pressure of the lungs is increased, thereby requiring greater inspiratory muscle activity [43]. Impaired gas exchange occurs as a result of destruction of the pulmonary capillary bed or thickening of the alveolar capillary membrane, causing ventilation/perfusion mismatch, oxygen diffusion limitation, and low mixed venous partial pressure of oxygen. Circulatory limitation resulting from pulmonary capillary destruction and hypoxic vasoconstriction leading to pulmonary hypertension and cardiac dysfunction also plays an important role in exercise limitation [43].

Relatively reduced lung compliance and inspiratory muscle weakness have been suggested as potential contributing factors of abnormal ventilatory mechanisms in pulmonary vascular diseases. During exercise, there is substantial arterial oxygen desaturation causing widening of alveolar-arterial oxygen tension, reflecting considerable

VA/Q

inequalities. Circulatory limitation resulting from pulmonary capillary destruction and hypoxic vasoconstriction leading to pulmonary hypertension and cardiac dysfunction also plays an important role in exercise limitation [3, 43].

3. Conclusions

The available literature suggests that in the majority of patients with severe chronic lung disease, primarily ventilatory constraints, resulting from the imbalance between ventilatory demand and capacity, limit physical capacity due to intense dyspnea sensations, whereas to a lesser extent, inadequate energy supply to locomotor muscles and/or locomotor muscle dysfunction limit(s) physical activity performance secondary to locomotor muscle discomfort. In contrast, in many patients with mild and moderate chronic lung disease, both reduced energy supply to locomotor muscles associated with leg discomfort and ventilatory constraints causing breathlessness restrain exercise tolerance.

Acknowledgment

Thorax Foundation is funded by the Innovative Medicines Imitative (IMI) for the project entitled “Physical activity as a crucial patient-reported outcome in COPD.”

References

1. Whipp BJ, Wagner PD, Agusti A. European Respiratory Monograph. European Respiratory Society; 2007. Determinants of the physiological systems responses to muscular exercise in healthy subjects; pp. 30–34.

2. O’Donnell DE, Bertley JC, Chau LKL, Webb KA. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. American Journal of Respiratory and Critical Care Medicine. 1997;155(1):109–115. [PubMed]

3. O'Donnell DE, Ofir D, Laveneziana P. European Respiratory Monograph. European Respiratory Society; 2007. Patterns of cardiopulmonary response to exercise in lung diseases; pp. 69–92.

4. O'Donnell DE, Fitzpatrick M. Physiology of interstitial lung disease. In: Schwartz M, King TJ, editors. Interstitial Lung Disease. 4th edition. Hamilton, Canada: Decker; 2003.

5. O'Donnell DE. Exercise limitation and clinical exercise testing in chronic obstructive pulmonary disease. In: Weisman I, Zeballos R, editors. Progress in Respiratory Research. Basel, Switzerland: Karger; 2002. pp. 138–158.

6. O’Donnell DE, Webb KA. Breathlessness in patients with severe chronic airflow limitation; Physiologic correlations. Chest. 1992;102(3):824–831. [PubMed]

7. O’Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation: the role of lung hyperinflation. American Review of Respiratory Disease. 1993;148(5):1351–1357. [PubMed]

8. O'Donnell DE. Exertional breathlessness in chronic respiratory disease. In: Mahler DA, editor. Dyspnea. New York, NY, USA: 1998. pp. 99–147.

9. Wagner PD. Determinants of maximal oxygen transport and utilization. Annual Review of Physiology. 1996;58:21–50. [PubMed]

10. Mador MJ, Kufel TJ, Pineda L. Quadriceps fatigue after cycle exercise in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2000;161(2):447–453. [PubMed]

11. Nishiyama O, Taniguchi H, Kondoh Y, et al. Quadriceps weakness is related to exercise capacity in idiopathic pulmonary fibrosis. Chest. 2005;127(6):2028–2033. [PubMed]

12. Mainguy V, Maltais F, Saey D, et al. Peripheral muscle dysfunction in idiopathic pulmonary arterial hypertension. Thorax. 2010;65(2):113–117. [PubMed]

13. Killian KJ. Limitation to muscular activity in chronic obstructive pulmonary disease. European Respiratory Journal. 2004;24(1):6–7. [PubMed]

14. Gallagher CG. Exercise limitation and clinical exercise testing in chronic obstructive pulmonary disease. Clinics in Chest Medicine. 1994;15(2):305–326. [PubMed]

15. Johnson BD, Badr MS, Dempsey JA. Impact of the aging pulmonary system on the response to exercise. Clinics in Chest Medicine. 1994;15(2):229–246. [PubMed]

16. Johnson BD, Reddan WG, Pegelow DF, Seow KC, Dempsey JA. Flow limitation and regulation of functional residual capacity during exercise in a physically active aging population. American Review of Respiratory Disease. 1991;143(5 I):960–967. [PubMed]

17. Johnson BD, Reddan WG, Seow KC, Dempsey JA. Mechanical constraints on exercise hyperpnea in a fit aging population. American Review of Respiratory Disease. 1991;143(5):968–977. [PubMed]

18. ATS/ACCP. ATS/ACCP Statement on cardiopulmonary exercise testing. American Journal of Respiratory and Critical Care Medicine. 2003;167(2):211–277. [PubMed]

19. Harms CA. Does gender affect pulmonary function and exercise capacity? Respiratory Physiology and Neurobiology. 2006;151(2-3):124–131. [PubMed]

20. Wasserman K, Hansen JE, Sue DY. Exercise testing and interpretation: an overview. In: Weinberg WR, editor. Principles of Exercise Testing and Interpretation. Philadelphia, Pa, USA: Lippincott; 2005. pp. 1–9.

21. DeLorey DS, Babb TG. Progressive mechanical ventilatory constraints with aging. American Journal of Respiratory and Critical Care Medicine. 1999;160(1):169–177. [PubMed]

22. Babb TG, Viggiano R, Hurley B, Staats B, Rodarte JR. Effect of mild-to-moderate airflow limitation on exercise capacity. Journal of Applied Physiology. 1991;70(1):223–230. [PubMed]

23. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. European Respiratory Journal. 1998;12(4):799–804. [PubMed]

24. O’Donnell DE, D’Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2001;163(4):892–898. [PubMed]

25. Ofir D, Laveneziana P, Webb KA, Lam YM, O’Donnell DE. Mechanisms of Dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2008;177(6):622–629. [PubMed]

26. O’Donnell DE, Laveneziana P, Ora J, Webb KA, Lam YM, Ofir D. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage i COPD. Thorax. 2009;64(3):216–223. [PubMed]

27. Dillard TA, Piantadosi S, Rajagopal KR. Prediction of ventilation at maximal exercise in chronic air-flow obstruction. American Review of Respiratory Disease. 1985;132(2):230–235. [PubMed]

28. Laveneziana P, Parker CM, O’Donnell DE. Ventilatory constraints and dyspnea during exercise in chronic obstructive pulmonary disease. Applied Physiology, Nutrition and Metabolism. 2007;32(6):1225–1238. [PubMed]

29. MacIntyre NR. Mechanisms of functional loss in patients with chronic lung disease. Respiratory Care. 2008;53(9):1177–1184. [PubMed]

30. Evison H, Cherniack RM. Ventilatory cost of exercise in chronic obstructive pulmonary disease. Journal of Applied Physiology. 1968;25(1):21–27. [PubMed]

31. MacIntyre NR, Leatherman NE. Mechanical loads on the ventilatory muscles. A theoretical analysis. American Review of Respiratory Disease. 1989;139(4 I):968–973. [PubMed]

32. Palange P, Ward SA. Recommendations on the use of exercise testing in clinical practice. European Respiratory Journal. 2007;29(5):1066–1067.

33. Casaburi R, Wasserman K, Patessio A, Loli F, Zanaboni S, Donner CF. A new perspective in pulmonary rehabilitation: anaerobic threshold as a discriminant in training. European Respiratory Journal. 1989;2(supplement 7):S618–S623. [PubMed]

34. Casaburi R. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Medicine and Science in Sports and Exercise. 2001;33(7, supplement):S662–S670. [PubMed]

35. Casaburi R, Patessio A, Ioli F, Zanaboni S, Donner CF, Wasserman K. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. American Review of Respiratory Disease. 1991;143(1):9–18. [PubMed]

36. Casaburi R, Petty TL. Reductions in exercise lactic acidosis. In: Barstow T, Casaburi R, editors. Principles and Practice of Pulmonary Rehabilitation. Philadelphia, Pa, USA: 1993. pp. 50–65.

37. Gallagher CG. Exercise and chronic obstructive pulmonary disease. Medical Clinics of North America. 1990;74(3):619–641. [PubMed]

38. Maltais F, Simard AA, Simard C, et al. Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. American Journal of Respiratory and Critical Care Medicine. 1996;153(1):288–293. [PubMed]

39. O’Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. Journal of Applied Physiology. 2008;105(2):753–757. [PubMed]

40. O’Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2001;164(5):770–777. [PubMed]

41. West JB. State of the art: ventilation-perfusion relationships. American Review of Respiratory Disease. 1977;116(5):919–943. [PubMed]

42. Rice AJ, Thornton AT, Gore CJ, et al. Pulmonary gas exchange during exercise in highly trained cyclists with arterial hypoxemia. Journal of Applied Physiology. 1999;87(5):1802–1812. [PubMed]

43. Agusti AGN, Cotes J, Wagner PD. Responses to exercise in lung diseases. European Respiratory Monograph. 1997;2(6):32–50.

44. Begin P, Grassino A. Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary disease. American Review of Respiratory Disease. 1991;143(5):905–912. [PubMed]

45. Light RW, Mahutte CK, Brown SE. Etiology of carbon dioxide retention at rest and during exercise in chronic airflow obstruction. Chest. 1988;94(1):61–67. [PubMed]

46. De Troyer A, Leeper JB, McKenzie DK, Gandevia SC. Neural drive to the diaphragm in patients with severe COPD. American Journal of Respiratory and Critical Care Medicine. 1997;155(4):1335–1340. [PubMed]

47. Mountain R, Zwillich C, Weil J. Hypoventilation in obstructive lung disease. The role of familial factors. New England Journal of Medicine. 1978;298(10):521–525. [PubMed]

48. O’Donnell DE, D’Arsigny C, Fitzpatrick M, Webb KA. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. American Journal of Respiratory and Critical Care Medicine. 2002;166(5):663–668. [PubMed]

49. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises—part I: aging arteries: a “set up” for vascular disease. Circulation. 2003;107(1):139–146. [PubMed]

50. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises—part II: the aging heart in health: links to heart disease. Circulation. 2003;107(2):346–354. [PubMed]

51. Ferrazza AM, Martolini D, Valli G, Palange P. Cardiopulmonary exercise testing in the functional and prognostic evaluation of patients with pulmonary diseases. Respiration. 2009;77(1):3–17. [PubMed]

52. Naeije R. Pulmonary hypertension and right heart failure in chronic obstructive pulmonary disease. Proceedings of the American Thoracic Society. 2005;2(1):20–22. [PubMed]

53. Agusti AGN, Barbera JA, Roca J, Wagner PD, Guitart R, Rodriguez-Roisin R. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest. 1990;97(2):268–275. [PubMed]

54. Agusti AGN, Roca J, Gea J, Wagner PD, Xaubet A, Rodriguez-Roisin R. Mechanisms of gas-exchange impairment in idiopathic pulmonary fibrosis. American Review of Respiratory Disease. 1991;143(2):219–225. [PubMed]

55. D’Alonzo GE, Gianotti LA, Pohil RL. Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. Chest. 1987;92(1):57–62. [PubMed]

56. Dantzker DR, D’Alonzo GE. The effect of exercise on pulmonary gas exchange in patients with severe chronic obstructive pulmonary disease. American Review of Respiratory Disease. 1986;134(6):1135–1139. [PubMed]

57. Dantzker DR, D’Alonzo GE, Bower JS. Pulmonary gas exchange during exercise in patients with chronic obliterative pulmonary hypertension. American Review of Respiratory Disease. 1984;130(3):412–416. [PubMed]

58. Janicki JS. Influence of the pericardium and ventricular interdependence on left ventricular diastolic and systolic function in patients with heart failure. Circulation. 1990;81(2, supplement):15–20. [PubMed]

59. Dempsey JA, Harms CA, Ainsworth DM. Respiratory muscle perfusion and energetics during exercise. Medicine and Science in Sports and Exercise. 1996;28(9):1123–1128. [PubMed]

60. Harms CA, Babcock MA, McClaran SR, et al. Respiratory muscle work compromises leg blood flow during maximal exercise. Journal of Applied Physiology. 1997;82(5):1573–1583. [PubMed]

61. Neder JA, Jones PW, Nery LE, Whipp BJ. Determinants of the exercise endurance capacity in patients with chronic obstructive pulmonary disease: the power-duration relationship. American Journal of Respiratory and Critical Care Medicine. 2000;162(2):497–504. [PubMed]

62. Nery LE, Wasserman K, Andrews JD. Ventilatory and gas exchange kinetics during exercise in chronic airways obstruction. Journal of Applied Physiology Respiratory Environmental and Exercise Physiology. 1982;53(6):1594–1602. [PubMed]

63. Palange P, Galassetti P, Mannix ET, et al. Oxygen effect on O2 deficit and VO2 kinetics during exercise in obstructive pulmonary disease. Journal of Applied Physiology. 1995;78(6):2228–2234. [PubMed]

64. Roussos C, Macklem PT. The respiratory muscles. New England Journal of Medicine. 1982;307(13):786–797. [PubMed]

65. Puente-Maestu L, Tena T, Trascasa C, et al. Training improves muscle oxidative capacity and oxygenation recovery kinetics in patients with chronic obstructive pulmonary disease. European Journal of Applied Physiology. 2003;88(6):580–587. [PubMed]

66. Chiappa GR, Borghi-Silva A, Ferreira LF, et al. Kinetics of muscle deoxygenation are accelerated at the onset of heavy-intensity exercise in patients with COPD: relationship to central cardiovascular dynamics. Journal of Applied Physiology. 2008;104(5):1341–1350. [PubMed]

67. Wagner PD, Gale GE, Moon RE. Pulmonary gas exchange in humans exercising at sea level and simulated altitude. Journal of Applied Physiology. 1986;61(1):260–270. [PubMed]

68. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. European Respiratory Journal. 2008;31(3):492–501. [PubMed]

69. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. American Journal of Respiratory and Critical Care Medicine. 1996;153(3):976–980. [PubMed]

70. Hamilton AL, Killian KJ, Summers E, Jones NL. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. American Journal of Respiratory and Critical Care Medicine. 1995;152(6 I):2021–2031. [PubMed]

71. Bernard S, Leblanc P, Whittom F, et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 1998;158(2):629–634. [PubMed]

72. Serres I, Gautier V, Varray A, Préfaut C. Impaired skeletal muscle endurance related to physical inactivity and altered lung function in COPD patients. Chest. 1998;113(4):900–905. [PubMed]

73. Booth FW, Gollnick PD. Effects of disuse on the structure and function of skeletal muscle. Medicine and Science in Sports and Exercise. 1983;15(5):415–420. [PubMed]

74. Coyle EF, Martin WH, Bloomfield SA. Effects of detraining on responses to submaximal exercise. Journal of Applied Physiology. 1985;59(3):853–859. [PubMed]

75. Ottenheijm CA, Heunks LM, Sieck GC, et al. Diaphragm dysfunction in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2005;172(2):200–205. [PMC free article] [PubMed]

76. DeTroyer A, Pride N. The Thorax, Part C: Disease. 2nd edition. New York, NY, USA: Marcel Dekker; 1995. The chest wall and respiratory muscles in chronic obstructive pulmonary disease.

77. ATS. ATS statement: skeletal muscle dysfunction in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 1999;159:S1–S40. [PubMed]

78. Tiao G, Fagan JM, Samuels N, et al. Sepsis stimulates nonlysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle. Journal of Clinical Investigation. 1994;94(6):2255–2264. [PMC free article] [PubMed]

79. Llovera M, García-Martínez C, Agell N, López-Soriano FJ, Argilés JM. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochemical and Biophysical Research Communications. 1997;230(2):238–241. [PubMed]

80. Biolo G, Toigo G, Ciocchi B, et al. Metabolic response to injury and sepsis: changes in protein metabolism. Nutrition. 1997;13(9):S52–S57. [PubMed]

81. Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 1994;150(5 I):1453–1455. [PubMed]

82. De Godoy I, Donahoe M, Calhoun WJ, Mancino J, Rogers RM. Elevated TNF-α production by peripheral blood monocytes of weight-losing COPD patients. American Journal of Respiratory and Critical Care Medicine. 1996;153(2):633–637. [PubMed]

83. Schols AMWJ, Buurman WA, Staal-van Den Brekel AJ, Dentener MA, Wouters EFM. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51(8):819–824. [PMC free article] [PubMed]

84. Mitch WE, Goldberg AL. Mechanisms of disease: mechanisms of muscle wasting: the role of the ubiquitin-proteasome pathway. New England Journal of Medicine. 1996;335(25):1897–1905. [PubMed]

85. Vogiatzis I, Simoes DCM, Stratakos G, et al. Effect of pulmonary rehabilitation on muscle remodelling in cachectic patients with COPD. European Respiratory Journal. 2010;36(2):301–310. [PubMed]

86. Gosker HR, Kubat B, Schaart G, van der Vusse GJ, Wouters EFM, Schols AMWJ. Myopathological features in skeletal muscle of patients with chronic obstructive pulmonary disease. European Respiratory Journal. 2003;22(2):280–285. [PubMed]

87. Agustí AG, Sauleda J, Miralles C, et al. Skeletal muscle apoptosis and weight loss in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2002;166(4):485–489. [PubMed]

88. Jackson MJ, O’Farrell S. Free radicals and muscle damage. British Medical Bulletin. 1993;49(3):630–641. [PubMed]

89. Buck M, Chojkier M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO Journal. 1996;15(8):1753–1765. [PubMed]

90. Llesuy S, Evelson P, Gonzalez-Flecha B, et al. Oxidative stress in muscle and liver of rats with septic syndrome. Free Radical Biology and Medicine. 1994;16(4):445–451. [PubMed]

91. Engelen MPKJ, Schols AMWJ, Baken WC, Wesseling GJ, Wouters EFM. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. European Respiratory Journal. 1994;7(10):1793–1797. [PubMed]

92. Schols AMWJ, Soeters PB, Dingemans AMC, Mostert R, Frantzen PJ, Wouters EFM. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. American Review of Respiratory Disease. 1993;147(5):1151–1156. [PubMed]

93. Kelsen SG, Ference M, Kapoor S. Effects of prolonged undernutrition on structure and function of the diaphragm. Journal of Applied Physiology. 1985;58(4):1354–1359. [PubMed]

94. Vaz M, Thangam S, Prabhu A, Shetty PS. Maximal voluntary contraction as a functional indicator of adult chronic undernutrition. British Journal of Nutrition. 1996;76(1):9–15. [PubMed]

95. Fiaccadori E, Zambrelli P, Tortorella G. Physiopathology of respiratory muscles in malnutrition. Minerva Anestesiologica. 1995;61(3):93–99. [PubMed]

96. Openbrier DR, Irwin MM, Rogers RM. Nutritional status and lung function in patients with emphysema and chronic bronchitis. Chest. 1983;83(1):17–22. [PubMed]

97. Mitch WE, Medina R, Grieber S, et al. Metabolic acidosis stimulates muscle protein degradation by activating the adenosine triphosphate-dependent pathway involving ubiquitin and proteasomes. Journal of Clinical Investigation. 1994;93(5):2127–2133. [PMC free article] [PubMed]

98. Fiaccadori E, Coffrini E, Ronda N, et al. Hypophosphatemia in course of chronic obstructive pulmonary disease. Prevalence, mechanisms, and relationships with skeletal muscle phosphorus content. Chest. 1990;97(4):857–868. [PubMed]

99. Knochel JP. Neuromuscular manifestations of electrolyte disorders. American Journal of Medicine. 1982;72(3):521–535. [PubMed]

100. Fiaccadori E, Coffrini E, Fracchia C, Rampulla C, Montagna T, Borghetti A. Hypophosphatemia and phosphorus depletion in respiratory and peripheral muscles of patients with respiratory failure due to COPD. Chest. 1994;105(5):1392–1398. [PubMed]

101. Stendig Lindberg G, Bergstrom J, Hultman E. Hypomagnesaemia and muscle electrolytes and metabolites. Acta Medica Scandinavica. 1977;201(4):273–280. [PubMed]

102. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. American Journal of Respiratory and Critical Care Medicine. 1994;150(1):11–16. [PubMed]

103. Decramer M, De Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 1996;153(6):1958–1964. [PubMed]

104. Hall-Angeras M, Angeras U, Zamir O, Hasselgren PO, Fischer JE. Interaction between corticosterone and tumor necrosis factor stimulated protein breakdown in rat skeletal muscle, similar to sepsis. Surgery. 1990;108(2):460–466. [PubMed]

Articles from Pulmonary Medicine are provided here courtesy of
Hindawi Publishing Corporation